These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
365 related articles for article (PubMed ID: 27894373)
1. Cognitive effects of adjunctive N-acetyl cysteine in psychosis. Rapado-Castro M; Dodd S; Bush AI; Malhi GS; Skvarc DR; On ZX; Berk M; Dean OM Psychol Med; 2017 Apr; 47(5):866-876. PubMed ID: 27894373 [TBL] [Abstract][Full Text] [Related]
2. N-acetylcysteine in a Double-Blind Randomized Placebo-Controlled Trial: Toward Biomarker-Guided Treatment in Early Psychosis. Conus P; Seidman LJ; Fournier M; Xin L; Cleusix M; Baumann PS; Ferrari C; Cousins A; Alameda L; Gholam-Rezaee M; Golay P; Jenni R; Woo TW; Keshavan MS; Eap CB; Wojcik J; Cuenod M; Buclin T; Gruetter R; Do KQ Schizophr Bull; 2018 Feb; 44(2):317-327. PubMed ID: 29462456 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of adjunctive N-acetyl cysteine (NAC) on symptoms of chronic schizophrenia: A double-blind, randomized clinical trial. Sepehrmanesh Z; Heidary M; Akasheh N; Akbari H; Heidary M Prog Neuropsychopharmacol Biol Psychiatry; 2018 Mar; 82():289-296. PubMed ID: 29126981 [TBL] [Abstract][Full Text] [Related]
4. Effects of N-acetyl cysteine on cognitive function in bipolar disorder. Dean OM; Bush AI; Copolov DL; Kohlmann K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Berk M Psychiatry Clin Neurosci; 2012 Oct; 66(6):514-7. PubMed ID: 23066769 [TBL] [Abstract][Full Text] [Related]
5. Sex Differences in Verbal Memory Predict Functioning Through Negative Symptoms in Early Psychosis. Buck G; Lavigne KM; Makowski C; Joober R; Malla A; Lepage M Schizophr Bull; 2020 Dec; 46(6):1587-1595. PubMed ID: 32307536 [TBL] [Abstract][Full Text] [Related]
6. Impaired Context Processing is Attributable to Global Neuropsychological Impairment in Schizophrenia and Psychotic Bipolar Disorder. Reilly JL; Hill SK; Gold JM; Keefe RS; Clementz BA; Gershon E; Keshavan MS; Pearlson G; Tamminga CA; Sweeney JA Schizophr Bull; 2017 Mar; 43(2):397-406. PubMed ID: 27306316 [TBL] [Abstract][Full Text] [Related]
7. Investigating the association between neurocognition and psychosis in bipolar disorder: further evidence for the overlap with schizophrenia. Jabben N; Arts B; Krabbendam L; van Os J Bipolar Disord; 2009 Mar; 11(2):166-77. PubMed ID: 19267699 [TBL] [Abstract][Full Text] [Related]
8. Improvement of cognitive function in schizophrenia with Yolland COB; Phillipou A; Castle DJ; Neill E; Hughes ME; Galletly C; Smith ZM; Francis PS; Dean OM; Sarris J; Siskind D; Harris AWF; Rossell SL Nutr Neurosci; 2020 Feb; 23(2):139-148. PubMed ID: 29847303 [No Abstract] [Full Text] [Related]
9. Neuropsychological evidence for abnormal neurodevelopment associated with early-onset psychoses. Bombin I; Mayoral M; Castro-Fornieles J; Gonzalez-Pinto A; de la Serna E; Rapado-Castro M; Barbeito S; Parellada M; Baeza I; Graell M; Payá B; Arango C Psychol Med; 2013 Apr; 43(4):757-68. PubMed ID: 22831788 [TBL] [Abstract][Full Text] [Related]
10. Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder. Chengappa KN; Bowie CR; Schlicht PJ; Fleet D; Brar JS; Jindal R J Clin Psychiatry; 2013 Nov; 74(11):1076-83. PubMed ID: 24330893 [TBL] [Abstract][Full Text] [Related]
11. N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial. Berk M; Copolov D; Dean O; Lu K; Jeavons S; Schapkaitz I; Anderson-Hunt M; Judd F; Katz F; Katz P; Ording-Jespersen S; Little J; Conus P; Cuenod M; Do KQ; Bush AI Biol Psychiatry; 2008 Sep; 64(5):361-8. PubMed ID: 18436195 [TBL] [Abstract][Full Text] [Related]
13. Neuropsychological functioning in early and chronic stages of schizophrenia and psychotic bipolar disorder. Menkes MW; Armstrong K; Blackford JU; Heckers S; Woodward ND Schizophr Res; 2019 Apr; 206():413-419. PubMed ID: 31104720 [TBL] [Abstract][Full Text] [Related]
14. Adjunctive Pregnenolone Ameliorates the Cognitive Deficits in Recent-Onset Schizophrenia: An 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Kreinin A; Bawakny N; Ritsner MS Clin Schizophr Relat Psychoses; 2017; 10(4):201-210. PubMed ID: 24496044 [TBL] [Abstract][Full Text] [Related]
15. Executive attention deficits in schizophrenia: putative mandatory and differential cognitive pathology domains in medicated schizophrenia patients. Meiron O; Hermesh H; Katz N; Weizman A Psychiatry Res; 2013 Aug; 209(1):1-8. PubMed ID: 23102537 [TBL] [Abstract][Full Text] [Related]
16. Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Torrent C; Martinez-Arán A; Daban C; Amann B; Balanzá-Martínez V; del Mar Bonnín C; Cruz N; Franco C; Tabarés-Seisdedos R; Vieta E Compr Psychiatry; 2011; 52(6):613-22. PubMed ID: 21295774 [TBL] [Abstract][Full Text] [Related]
17. Effects of 12-month, double-blind N-acetyl cysteine on symptoms, cognition and brain morphology in early phase schizophrenia spectrum disorders. Breier A; Liffick E; Hummer TA; Vohs JL; Yang Z; Mehdiyoun NF; Visco AC; Metzler E; Zhang Y; Francis MM Schizophr Res; 2018 Sep; 199():395-402. PubMed ID: 29588126 [TBL] [Abstract][Full Text] [Related]
18. Metabolite profiles in the anterior cingulate cortex of depressed patients differentiate those taking N-acetyl-cysteine versus placebo. Das P; Tanious M; Fritz K; Dodd S; Dean OM; Berk M; Malhi GS Aust N Z J Psychiatry; 2013 Apr; 47(4):347-54. PubMed ID: 23341476 [TBL] [Abstract][Full Text] [Related]
19. Towards stage specific treatments: effects of duration of illness on therapeutic response to adjunctive treatment with N-acetyl cysteine in schizophrenia. Rapado-Castro M; Berk M; Venugopal K; Bush AI; Dodd S; Dean OM Prog Neuropsychopharmacol Biol Psychiatry; 2015 Mar; 57():69-75. PubMed ID: 25315856 [TBL] [Abstract][Full Text] [Related]
20. N-acetylcysteine as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study. Farokhnia M; Azarkolah A; Adinehfar F; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Sadeghi SM; Moghadam M; Gharibi F; Mirshafiee O; Akhondzadeh S Clin Neuropharmacol; 2013; 36(6):185-92. PubMed ID: 24201233 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]